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ABSTRACT  
Objective: In the present research work, fast dissolving tablets of Piroxicam were formulated by two different techniques i.e. direct 
compression method and sublimation method using different superdisintegrants.  
Methods: Twelve formulations were prepared (PXM1 to PXM12) in which first six formulation were prepared by direct compression technique 
and other six formulation were prepared by sublimation method by using camphor as a sublimating agent.  
Result and Discussion: All the formulations were subjected for precompression, post compression parameters, and shows all the data within 
the specific limits. Formulation PXM4 containing 5 % crospovidone showed 99.480 ± 0.291 % drug release in 20 min which was mo re than the 
drug release of rest of the formulations. The optimized formulation PXM4 was compared with the marketed formulation and it revealed that 
drug release of PXM4 was found to be 99.397 ± 0.751 % in 20 min, which was greater than the marketed formulation. Finally, results were 
statistically analysed by the application of one way ANOVA and t-test. The stability study of the optimized formulation PXM4 showed no 
significant changes in, drug content, disintegration time and in-vitro drug release.  
Conclusion: Piroxicam can be successfully prepared using direct compression technique and it will enhance the drug dissolution, which will 
further increase absorption and bioavailability of the drug. 
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A modern enhancement in Novel Drug Delivery System 
(NDDS) goals to improve safety and efficiency of formerly 
used drug molecule by formulating a suitable dosage form to 
achieve better patient acquiescence and ease of 
administration with enhanced bioavailability and enhanced 
efficacy, thus reducing the dose to reduce the side effects.1 
Due to the unique properties, the Fast dissolving drug 
delivery system (FDDDS) has great reputation in the 
pharmaceutical industry.2 FDDDS in most cases is a tablet 
that dissolved in oral mucosa within seconds without need of 
water that makes them extremely attractive to pediatric and 
geriatric patients.3, 4 Nowadays, the demand of fast 
disintegrating tablets has immensely increased as it has 
major impact on patient compliance.5 According to European 
Pharmacopoeia, rapidly disintegrating tablets are those, 
which are placed in the oral cavity and disperse before 
swallowing in less than three minutes.4 The property of 
dispersibility is due to the addition of superdisintegrants to 
the dosage form, thus increasing the bioavailability by 
releasing the drug in mouth.6, 7 There are various 
conventional approaches to formulate the fast dissolving 
tablets. Addition of superdisintegrants is the basic approach 
that plays a vital role in the dissolution and disintegration for 
the development of the fast dissolving tablets. This is the 
most popular technique due to its cost effectiveness and easy 
implementation.8, 9 Drugs which are poorly water soluble 
(Class II) having slower rate of absorption, high permeability 
and low bioavailability due to less dissolution, so there is 
need to improve the dissolution rate of such drugs which 
may lead to the improvement of bioavailability and hence 
faster onset of action of drugs is achieved.10 
Piroxicam, an oxicam is a non-selective cyclooxygenase – 2 
inhibitor, used in the treatment of rheumatoid arthritis, 
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osteoarthritis and other joint diseases but at high 
concentrations also inhibits polymorphonuclear leukocyte 
migration, decreases oxygen radical production, and inhibits 
lymphocyte function and it belongs to class-II of 
biopharmaceutical classification system which have low 
aqueous solubility.11 Therefore, the present research work is 
to formulate and evaluate of fast dissolving tablets Piroxicam 
in order to provide faster on set of action and better patient 
compliance. 
MATERIALS AND METHODS 
Piroxicam was obtained as gift sample from Lark 
laboratories, Bhiwadi, India. Sodium starch glycolate, 
croscarmellose sodium, microcrystalline stearate were 
obtained as gift sample from Maple biotech, Pune. Talc, 
camphor, mannitol and aspartame were procured from CHD 
fine chemicals, New Delhi and all other chemicals/solvents 
used were of analytical grade. 
Preformulation Studies 
All the Preformulation studies like melting point, solubility 
study, and partition coefficient were carried out 
effectively.12-14 
Determination of max in methanol and phosphate buffer 
pH 6.8 
The absorption maxima of Piroxicam was determined in 
methanol and phosphate buffer pH 6.8 by scanning the drug 
in the range of 400-200 nm using UV spectrophotometer. 
Preparation of stock solution and calibration curve of 
Piroxicam 
Standard stock solution (100 µg/ml) of Piroxicam was 
prepared in phosphate buffer pH 6.8. From this stock 
solution of phosphate buffer pH 6.8 different aliquots of 
various concentration (6, 8, 10, 12, 14, 16, 20 µg/ml) were 
prepared. For phosphate buffer pH 6.8 absorbance was 
measured at 344 nm, against similarly treated blank.  
Compatibility Studies of Piroxicam 
Dried samples were mixed with dried potassium bromide 
(KBr) powder. The sample discs were prepared using KBr 
press at pressure of 10000 to 15000 psi. The sample disc was 
placed in the sample holder and scanned from 4000 to 400 
cm-1 at a resolution of 4 cm-1.15 
Formulation of Tablets 
Fast dissolving tablets of Piroxicam were formulated by 
direct compression method and sublimation method using 
sublimating agent i.e. camphor. Different superdisintegrants 
were used (Sodium starch glycolate, crospovidone and 
croscarmellose sodium) with different concentration. In the 
present work, total 12 formulations were prepared i.e. PXM1 
to PXM12 in which formulations PXM1 to PXM6 were 
prepared by direct compression method and PXM7 to PXM 




Table 1: Composition of different batches of fast dissolving tablets of Piroxicam (Direct compression method) 








PXM5 (mg) PXM6 (mg) 
1 Piroxicam 20 20 20 20 20 20 
2 SSG 6 10 - - - - 
3 CP - - 6 10 - - 
4 CCS - - - - 6 10 
5 MCC 102 98 102 98 102 98 
6 Mannitol 60 60 60 60 60 60 
7 Aspartame 8 8 8 8 8 8 
8 Magnesium stearate 2 2 2 2 2 2 
9 Talc 2 2 2 2 2 2 
10 Menthol q.s q.s q.s q.s q.s q.s 
 
Table 2: Composition of different batches of fast dissolving tablets of Piroxicam (Sublimation method) 












1 Piroxicam 20 20 20 20 20 20 
2 SSG - - 6 10 - - 
3 CP 6 10 - - - - 
4 CCS - - - - 6 10 
5 MCC 96 92 96 92 96 92 
6 Mannitol 60 60 60 60 60 60 
7 Aspartame 8 8 8 8 8 8 
8 Magnesium stearate 2 2 2 2 2 2 
9 Talc 2 2 2 2 2 2 
10 Camphor 6 6 6 6 6 6 
SSG-Sodium starch glycolate, CP-Crospovidone, CCS-Croscarmellose sodium, MCC-Microcrystalline cellulose. 
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Pre-Compression Studies 
Pre-compression studies like bulk density, tapped density, 
angle of repose, carr’s index and hausner ration were carried 
out successfully.19-23 
Post Compression Studies 
The prepared tablets were evaluated for post compression 
studies, which are as follows: 
Weight variation:  
Randomly 20 tablets were selected from each formulation 
and weighed individually. Average weight was calculated 
and comparison was made between individual weight and 
average weight of tablets.24 
Thickness:  
The thickness was measured by placing tablet between two 
arms of the Vernier Caliper.25 
Hardness: 
The hardness of tablets was measured by Monsanto 
hardness tester.26 
Friability:  
Randomly twenty tablets were selected and weighed. These 
tablets were placed in the Roche friabilator test apparatus, 
which was then operated at 25 revolutions in a minute. After 
completion of 100 revolutions, the tablets were dusted and 
re-weighed.27 The percent friability was calculated from the 
formula: 
               
                          
              
     
Drug content:  
Ten tablets from each formulation were crushed and the 
blend equivalent to one tablet was taken. The blend 
equivalent to one tablet was taken in a 100 ml volumetric 
flask and volume was made up to mark with phosphate 
buffer (pH 6.8). The flask was shaken for 24 hrs using a 
water bath shaker. The solution was filtered and the filtrate 
was analyzed at 344 nm against similarly treated blank 
using UV-VIS spectrophotometer.28 
In-vitro disintegration time 
Six tablets were taken from all formulations and maintaining 
the water temperature at 37.0 ± 0.5 oC. Time taken for 
complete the disintegration of tablets was recorded by 
stopwatch. For accuracy, an average of six tablets was 
taken.29 
Wetting time:  
To determine the wetting time of tablets, five pieces of 
circular tissue paper was placed in the petri dish of diameter 
10 cm containing 2 ml of amaranth dye and 10 ml of 
simulated saliva. The amaranth dye was used to identify 
complete wetting of the tablet surface. Now, the tablet was 
placed on the surface of the tissue paper in the petri dish 
containing dye at room temperature. The time-required dye 
to reach the upper surface of the tablets and the complete 
wetting of tablet was noted as the wetting time.29 
Water absorption ratio:  
For the determination of water absorption ratio, firstly 
weighed the tablets from each formulation before placing 
them into the petri plate containing 2 ml of amaranth dye 
and 10 ml of simulated saliva. Tablets were carefully 
removed from petri dish and weigh the wetted tablet.29 The 
water absorption ratio was calculated using the formula:  
  
     
  
      
Where, R is water absorption ratio,    is weight of tablet 
before water absorption, and    is weight of tablet after 
water absorption. 
In-vitro dissolution studies: 
In-vitro dissolution study was carried out using USP 
dissolution test apparatus II at 50 rpm in 900 ml of 
phosphate buffer (pH 6.8) as a dissolution media and the 
temperature was maintained at 37 ± 0.5 ºC. The samples 
were withdrawn at fixed time intervals of 0, 5, 10, 15, 20 
min. Aliquots (10 ml) were withdrawn, filtered and analyzed 
spectrophotometrically using UV spectrophotometer at 344 
nm. An equal amount of fresh dissolution medium, pre-
warmed at 37 ± 0.5 ºC, was added after each sampling to 
maintain the sink condition throughout the study.30 The 
premising formulation was compared with the two different 
brands of marketed formulation by comparing in-vitro drug 
release. 
Statistical analysis  
The optimized formulation was analyzed using graph pad 
prism 7.0 version to generate statistical data. ANOVA was 
used to identify the significant effect. One way ANOVA, 
Brown-Forsythe test and Bartlett’s test was used to analyze 
the data and the P value was calculated at P < 0.05 to identify 
the significant effect.31 
Stability study of optimized batch 
To determine the drug and formulation stability, stability 
studies was performed according to ICH guideline under 
accelerated storage conditions. Tablets from the optimized 
batch were stored in stability chamber at temperature 45.0 
°C ± 2.0 °C and 75 % ± 5 % RH conditions for the period of 
90 days. After 90 days, the tablets were evaluated for the 
physical appearance, drug content, and disintegration time 
and in-vitro drug release.17 
RESULTS AND DISCUSSION 
Pre-formulation parameters 
Piroxicam was observed for organoleptic properties like 
physical appearance, odor, and melting point. The drug was 
identified with the help of UV and FTIR and exhibited 
absorption maxima at 344 nm when phosphate buffer 6.8pH 
was used as a solvent as mentioned in the literature. 
Differential scanning calorimeter shows endothermic fusion 
peak at 202.3°C, which was corresponding to the melting 
point of Piroxicam. 
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Figure 1: DSC Chromatogram of Piroxicam 
 
Figure 2: UV scan spectrum of Piroxicam in phosphate buffer pH 6.8 
 
Table 3: Calibration curve data of Piroxicam in 
phosphate buffer pH 6.8 
Concentration 
(µg/ml) 
Absorbance ± SD 
(n=3) 
 0 0 
6 0.222 ± 0.001 
8 0.249 ± 0.001 
10 0.359 ± 0.001 
12 0.413 ± 0.001 
 14 0.480 ± 0.001 
16 0.554 ± 0.001 
  18 0.620 ± 0.001 
20 0.689 ± 0.001 
 
 
Figure 3: Calibration curve of Piroxicam in phosphate 
buffer pH 6.8
 
Table 4: Solubility studies of Piroxicam in different solvents 
Sr. NO. Solvent used Solubility (mg/ml) Solubility profile 
1 Methanol 7.26  Soluble 
2 Water (pH 7.0) 0.022  Very slightly soluble 
3 Phosphate buffer pH 6.8 0.236  Slightly soluble 
4 pH 4.0 0.029  Very slightly soluble 
5 pH 7.0 0.556  Slightly soluble 
6 0.1N HCl 0.417  Slightly soluble 
 
y = 0.0344x + 0.0006 
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Drug excipient compatibility study by FTIR 
The IR spectrum of physical mixture of pure drug and 
excipients were recorded by IR spectroscopy. The IR 
spectrum of drug and excipients did not show any significant 
change in the characteristic peaks of drug, which showed 
that superdisintegrants and drug were compatible with each 
other (Figure 4). 
 
Table 5: Infrared spectral band of Piroxicam 
Sr.No. Functional group Observed peaks (cm-1) 
Reported peaks  
(cm-1) 
1 Ortho-di substituted ring 773.46 775 
2 SO2-NH group 1149.57 1149 
3 Pyridine 1300.02 1298 
4 Methyl 1435.04 1435 
5 Tertiary amine group 1525.69 1524 
6 Amide carbonyl 1629.85 1629.85 
7 Cubic polymorphic form 3338.78 3338.78 
 
Table 6: FTIR studies of Piroxicam with superdisintegrants 
IR spectra 
Peak of functional groups [Wave length (cm-1)] 
N-H stretch CH stretch C=C stretch OH bend 
Standard spectra 3339.028 2933.879 1529.315 939.582 
Piroxicam 3338.78 2931.88 1525.69 939.33 
Piroxicam + CCS 3337.96 2932.89 1529.62 938.41 
Piroxicam + crospovidone 3337.96 2933.85 1530.58 938.41 
Piroxicam + SSG 3337.96 2932.89 1531.55 938.41 
 
Precompression parameters 
The values of precompression parameters evaluated were found to be within the prescribed limits and indicated good free 
flowing property. Data are tabulated in Table 7. 
 
Figure 4: FTIR spectrum of (a) PXM, (b) SSG and PXM, (c) CP and PXM, (d) CCS and PXM 
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Table 7: Precompression parameters of powder blend 
Formulation 
code 






Hausner’s ratio Carr’s index (%) 
PXM1 31.63 ± 0.563 0.326 ± 0.009 0.376 ± 0.011 1.15 ± 0.010 13.37 ± 0.495 
PXM2 30.55 ± 0.527 0.376 ± 0.018 0.437 ± 0.017 1.15 ± 0.012 13.89 ± 0.870 
PXM3 28.58 ± 0.450 0.342 ± 0.019 0.423 ± 0.021 1.23 ± 0.005 19.143 ± 0.491 
PXM4 28.15 ± 0.30 0.357 ± 0.015 0.411 ± 0.018 1.13 ± 0.030 13.13 ± 0.253 
PXM5 27.88 ± 0.627 0.444 ±0.013 0.526 ± 0.015 1.173 ± 0.001 14.75 ± 0.108 
PXM6 25.41 ± 0.685 0.457 ± 0.015 0.553 ± 0.018 1.21 ± 0.003 17.367 ± 0.220 
PXM7 30.240 ± 0.617 0.561 ± 0.003 0.646 ± 0.006 1.152 ± 0.005 13.197 ± 0.336 
PXM8 28.990 ± 0.298 0.620 ± 0.006 0.705 ± 0.004 1.136 ± 0.004 12.007 ± 0.332 
PXM9 33.170 ± 0.706 0.478 ± 0.002 0.558 ± 0.003 1.167 ± 0.003 14.383 ± 0.224 
PXM10 26.880 ± 0.355 0.508 ± 0.002 0.624 ± 0.018 1.182 ± 0.006 15.427 ± 0.42 
PXM11 27.967 ± 0.182 0.410 ± 0.005 0.493 ± 0.009 1.197 ± 0.005 16.497 ± 0.341 
PXM12 27.697 ± 0.405 0.517 ± 0.007 0.590 ± 0.007 1.140 ± 0.008 12.263 ± 0.617 
Mean ± SD (n=3) 
 
Post compression parameters 
Post-compression evaluations of all formulations were carried out successfully and data are tabulated Table 8 and Table 9 
respectively. 





Friability (% age)  Thickness (mm)  
Weight 
variation  
Drug content (%)  
PXM1 3.500 ± 0.300 0.534 ± 0.093 3.546 ± 0.069 Pass 98.730 ± 0.611 
PXM2 3.067 ± 0.208 0.568 ± 0.034 3.569 ± 0.068 Pass 99.36 ± 0.959 
PXM3 3.467 ± 0.115 0.480 ± 0.076   3.464 ± 0.053 Pass 100.24 ± 0.641 
PXM4 3.500 ± 0.173 0.375 ± 0.144 3.552 ± 0.045 Pass 100.19 ± 0.386 
PXM5 3.900 ± 0.100 0.659 ± 0.191 3.425 ± 0.034 Pass 99.850 ± 0.200 
PXM6 3.800 ± 0.300 0.672 ± 0.016   3.457 ± 0.038 Pass 99.250 ± 0.522 
PXM7 3.467 ± 0.896 0.593 ± 0.042 3.376 ± 0.053 Pass 97.033 ± 0.533 
PXM8 3.500 ± 0.781 0.579 ± 0.049 3.390 ± 0.047 Pass 99.157 ± 0.400 
PXM9 3.630 ± 0.551 0.775 ± 0.056 3.392 ± 0.040 Pass 99.037 ± 0.352 
PXM10 4.430 ± 0.777 0.787 ± 0.027 3.367 ± 0.026 Pass 99.020 ± 0.052 
PXM11 3.760 ± 0.379 0.643 ± 0.049 3.418 ± 0.059 Pass 98.773 ± 0.336 
PXM12 3.860 ± 0.306 0.654 ± 0.024 3.369 ± 0.040 Pass 99.497 ± 0.517 
Mean ± SD (n=3),  
 





Wetting time (sec) Water Absorption Ratio 
(%) 
PXM1 54.787 ± 0.514 23.987 ± 0.991 64.813 ± 0.836 
PXM2 46.23 ±  0.404 19.840 ± 0.643 73.397 ± 0.309 
PXM3 33.8 ± 0.625 26.050 ± 0.821 73.420 ± 0.305 
PXM4 18.667 ± 0.577 10.410 ± 0.637 94.997 ± 0.154 
PXM5 58.35 ± 0.673 57.66 ± 0.577 71.070 ± 0.298 
PXM6 60.700 ± 0.608 42.673 ± 0.769 62.127 ± 0.633 
PXM7 51.200 ± 0.779 56.267 ± 0.681 65.867 ± 0.351 
PXM8 38.100 ± 0.850 43.467 ± 0.961 83.700 ± 0.458 
PXM9 66.300 ± 0.557 68.600 ± 0.794 55.100 ± 0.624 
PXM10 59.900 ± 0.500 62.067 ± 0.513 62.133 ± 0.351 
PXM11 71.067 ± 0.416 72.700 ± 0.458 69.600 ± 0.700 
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Dissolution studies were conducted for all the formulation 
via USP dissolution apparatus II paddle type, using 
phosphate buffer pH 6.8 as dissolution medium. It had been 
observed from the drug release profile more than 90 % drug 
was released within 20 min. Tablets which were formulated 
by the direct compression method showed more than 75 % 
of the drug release within 15 min. Formulation PXM4 
containing 5 % crospovidone showed 99.450 ± 0.260 % drug 
release within 15 min which was formulated by the direct 
compression method. Formulation PXM8 that was 
formulated by sublimation method containing 5 % 
crospovidone and 3 % camphor as sublimating agent 
showed 95.94 ± 0.205 % drug release within 15 min that 
was less as compared to the formulation PXM4. Cumulative 
percent drug release of all formulations is tabulated below in 
Table 10. Comparative drug release of the all the 
formulations were showed in the Figure 5. 
 




0 5 10 15 20 
PXM1 0 60.280 ± 0.567 67.893 ± 0.787 79.260 ± 0.910 96.043 ± 0.614 
PXM2 0 63.240 ± 0.490 71.107 ± 0.510 87.113 ± 0.345 99.040 ± 0.445 
PXM3 0 63.050 ± 0.790 75.050 ± 0.753 83.193 ± 0.710 98.057 ± 0.819 
PXM4 0 68.950 ± 0.785 85.163 ± 0.550 99.450 ± 0.260 99.480 ± 0.291 
PXM5 0 60.980 ± 0.516 74.667 ± 0.451 81.370 ± 0.488 96.427 ± 0.407 
PXM6 0 63.14 ± 0.651 76.687 ± 0.539 86.920 ± 0.570 99.087 ± 0.619 
PXM7 0 54.22 ± 0.477 68.60 ± 0.484 85.24 ± 0.514 93.26 ± 0.462 
PXM8 0 77.06 ± 0.385 88.04 ± 0.118 95.94 ± 0.205 99.09 ± 0.140 
PXM9 0 51.00 ± 0.811 64.25 ± 0.715 73.66 ± 0.728 88.34 ± 0.558 
PXM10 0 56.22 ± 0.293 71.80 ± 0.210 82.73 ± 0.400 94.83 ± 0.401 
PXM11 0 51.10 ± 0.394 68.08 ± 0.346 84.07 ± 0.681 93.20 ± 0.433 
PXM12 0 64.67 ± 0.548 78.55 ± 0.513 89.17 ± 0.201 96.64 ± 0.557 
        Mean (%CDR) ± SD (n=3),  
 
 
Figure 5: Comparison of percent cumulative drug release of all the formulations PXM1 to PXM12 
 
From the above data, it was observed that formulation PXM 
4 containing 5 % crospovidone formulated by the direct 
compression method showed fastest drug release when 
compared with the all other formulations. The best-selected 
formulation PXM 4 was chosen for comparison with 
marketed formulations. Formulation PXM4 was compared 
with two different marketed formulations of different 
brands. Comparison indicated that the prepared formulation 
PXM4 containing 5 % crospovidone showed 99.667 ± 0.244 
% drug release in 15 min whereas marketed formulation 
MKT1 and MKT2 showed 89.017± 0.091 % and 85.013 ± 
0.119 % drug release within 15 min that was less than 
formulation PXM4. The comparison of percent drug release 
of optimized formulation with marketed formulation is 





























Kumar et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):17-25 
ISSN: 2250-1177                                                                                  [24]                                                                                 CODEN (USA): JDDTAO 
Table 11: Comparison of the optimized formulation with the marketed formulations 
Time (min.) PXM4 MKT1 MKT2 
0 0 0 0 
5 76.900 ± 0.324 72.993 ± 0.206 68.530 ± 0.426 
10 87.330 ± 0.361 81.737 ± 0.555 76.993 ± 0.111 
15 99.667 ± 0.244 89.017 ± 0.091 85.013 ± 0.119 
20 99.397 ± 0.751 90.950 ± 0.060 95.003 ± 0.179 
 
 
Figure 6:  Comparison of the optimized formulation with the marketed formulations 
 
Statistical analysis 
It was found to be significant indicating there is no 
significant difference in the release profile of formulated 
FDTs and marketed formulations.  
Stability study of optimized formulation 
The optimized formulation PXM4 The fast dissolving tablets 
were packed in suitable packaging and stored at 40.0 °C ± 
2.0 °C and RH 75 % ± 5 % for 90 days. After 90 days the 
tablets were evaluated for physical appearance, drug 
content, disintegration time, wetting time and in-vitro drug 
release studies. Stability data for the optimized formulation 
is shown in the Table 12. No significant changes were seen in 
drug content, disintegration time, wetting time and in-vitro 
drug release. Stability study of optimized formulation PXM4 
was found to be stable and compiles with Pharmacopeias 
standards. 
Table 12: Drug release from the formulation PXM4 
during stability studies 
Sampling time (90 days) 
Time (min.) % CPR ± SD (n=3) 
0 0 
5 66.163 ± 0.280 
10 82.257 ± 0.435 
15 94.320 ± 0.802 
20 97.120 ± 0.147 
 
CONCLUSION 
Fast dissolving tablets were prepared in two different 
methods viz. direct compression and sublimation. Pre-
formulations parameters like the physical characterization 
of the drug were evaluated. All the Piroxicam fast dissolving 
tablets were showed more than 80 % drug release within 
the 15 min. Formulation PXM4 containing 5 % crospovidone 
prepared by direct compression was found to be better in 
terms of rapid disintegration and maximum percentage drug 
release when compared with all other formulations and 
marketed formulation. It shows disintegration time of 
18.667 ± 0.577 sec and 99.450 ± 0.260 % drug release in 15 
min. Stability studies revealed that there were no significant 
changes seen in physical appearance, drug content, 
disintegration time and in-vitro drug release during the 
storage of optimized formulation PXM4 for 90 days. Thus, 
Piroxicam can be successfully prepared using direct 
compression technique and it will enhance the drug 
dissolution, which will further increase absorption and 
bioavailability of the drug. 
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